Pleural mesothelioma is a rare and aggressive cancer. The cancer with a poor prognosis is mainly caused by asbestos. Surgery is an important part of treating pleural mesothelioma, but the impact of surgery on patients’ survival is unclear and sparking debate. A recent study was presented at the World Conference[…]
Peritoneal Mesothelioma
Cell Mutations and Peritoneal Mesothelioma
Peritoneal mesothelioma is a hard cancer to treat because it is very aggressive and rare. It is usually found late due to it being rare and having unclear symptoms, making treatment very difficult. Current treatments that can include surgery and chemotherapy have limited success against the cancer. New ways to[…]
Mesothelioma Diagnosis
Mesothelioma is a rare and hard to diagnose cancer. There are many challenges patients and caregivers must face once someone is diagnosed with mesothelioma. There are expert guidelines that were recently updated by the International Mesothelioma Interest group. The group provides insights into mesothelioma’s diagnosis, which is incredibly valuable for[…]
Carcinogenicity of Forsterite Compared to Asbestos
Mesothelioma, a rare cancer caused by asbestos, continues to be a global health issue. The most common form of asbestos is chrysotile. Recent research looked at chrysotile and a heat-treated form called forsterite. This research can help with safer asbestos disposal in the future. A recent study examined whether forsterite,[…]
Genetic Testing for Mesothelioma
Mesothelioma is a serious cancer that affects the lining of certain organs and body cavities. It mainly affects older adults, but it can affect people of all ages. It is rare in children, but pediatric mesothelioma is still possible. A recent study looked at pediatric peritoneal mesothelioma. The study highlights[…]
CRS and HIPEC for Peritoneal Mesothelioma
Peritoneal mesothelioma is a rare and aggressive cancer linked to asbestos exposure. A promising option for treating the cancer includes cytoreductive surgery (CRS) with heated chemotherapy (HIPEC). A new article explains cytoreductive surgery and HIPEC for the treatment of peritoneal mesothelioma. Cytoreductive surgery removes as many tumors as possible. In[…]
Blood Biomarkers for Mesothelioma
A mesothelioma diagnosis is hard to receive and can be very overwhelming. Different research outcomes can help doctors and patients make better decisions though. One area of research is blood-based biomarkers. Two biomarkers that can help monitor mesothelioma include mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor[…]
Improving Mesothelioma Diagnosis
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos, mainly affects the pleura, the lining of the lungs. It also affects the peritoneum, which is the lining of the abdomen. It is very tough to diagnose mesothelioma, which leads to underdiagnosis of the disease. A study in Brazil’s Sao Paulo[…]
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
CRS-HIPEC for the Treatment of Peritoneal Mesothelioma
Researchers are studying the effectiveness of a multimodal treatment for peritoneal mesothelioma. The therapy involves cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC. Peritoneal mesothelioma is cancer of the abdominal lining. It is caused by inhaled or ingested asbestos fibers that travel to the lining of the abdomen. Over time,[…]
